Photodynamic Priming Modulates Endothelial Cell–Cell Junction Phenotype for Light-activated Remote Control of Drug Delivery

Inglut, Collin T.; Gray, Kelsey M.; Vig, Shruti; Jung, Jae Woo; Stabile, Jillian; Zhang, Yuji; Stroka, Kimberly M.; Huang, Huang‐Chiao

doi:10.1109/jstqe.2020.3024014

Cited by 11 publications

(12 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This direct pathway to cell death suggests that PDT is effective even against chemoresistant cancer cells characterized by defective signaling pathways, as long as there is sufficient light and intracellular photosensitizer. BPD-based PDT has been shown to reverse chemoresistance, synergize with chemotherapy and biological agents, and improve drug transport to tumors [27] , [28] , [29] , [30] , [31] , [32] . It has also been demonstrated that BPD-based PDT can mitigate the surges in pro-tumorigenic CD44 and CXCR4 expression in human pancreatic tumors after multiple cycles of chemotherapy [33] .…”

Section: Introductionmentioning

confidence: 99%

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Baglo

Sorrin

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

Highlights Combination of olaparib and photodynamic therapy is effective in reducing the number and clonogenic survival of ovarian cancer cells. Photodynamic therapy using a lipidated photosensitizer reduces the selective advantage of olaparib-resistant ovarian cancer cells. Photodynamic therapy potentiates the DNA-damaging effects of olaparib.

show abstract

Section: Introductionmentioning

confidence: 99%

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Baglo

Sorrin

et al. 2021

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…We previously demonstrated that low‐dose PDT priming allows transient opening of the BBB through reversible modulation of endothelial cell‐cell junction phenotype. [ 36 ] After demonstrating the superiority of NanoVP‐PDT in our mouse model of GBM, we investigated the ability of low‐dose NanoVP‐PDT to permeabilize the BBB more distantly from the site of light irradiation. In the clinic, this may permit enhanced drug delivery to tumor cells intercalated with healthy brain stroma that are not close enough to the light source to be killed.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, non‐tumor‐bearing animals that received 125 mg kg −1 5‐ALA and 54 J experienced a 50% mortality rate within 5 days of treatment. We demonstrated that NanoVP‐PDT at subtherapeutic doses to achieve photodynamic priming [ 36 , 70 ] mediates BBB opening to increase model drug accumulation in the brain by 5.5‐fold compared to using 5‐ALA‐PDT. More importantly, we showed that low‐dose PDT using NanoVP did not result in healthy brain tissue damage, consistent with findings in low‐dose 5‐ALA‐PDT‐treated rats.…”

Section: Discussionmentioning

confidence: 99%

Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Quinlan,

Inglut,

Srivastava

et al. 2024

Advanced Science

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or inducing biological changes. PDT can ablate unresectable GBM and sensitize tumors to chemotherapy. Verteporfin (VP) is a promising photosensitizer that relies on liposomal carriers for clinical use. While lipids increase VP's solubility, they also reduce intracellular photosensitizer accumulation. Here, a pure‐drug nanoformulation of VP, termed “NanoVP”, eliminating the need for lipids, excipients, or stabilizers is reported. NanoVP has a tunable size (65–150 nm) and 1500‐fold higher photosensitizer loading capacity than liposomal VP. NanoVP shows a 2‐fold increase in photosensitizer uptake and superior PDT efficacy in GBM cells compared to liposomal VP. In mouse models, NanoVP‐PDT improved tumor control and extended animal survival, outperforming liposomal VP and 5‐aminolevulinic acid (5‐ALA). Moreover, low‐dose NanoVP‐PDT can safely open the blood‐brain barrier, increasing drug accumulation in rat brains by 5.5‐fold compared to 5‐ALA. NanoVP is a new photosensitizer formulation that has the potential to facilitate PDT for the treatment of GBM.

show abstract

“…In addition, the blood-brain barrier (BBB) is a formidable obstacle for the transport of most administered therapeutics to the brain (6,7), and most anti-tumor drugs have difficulty passing the BBB and the blood-brain tumor barrier (BBTB), it is a major hurdle in the development of targeted drugs for glioma (8)(9)(10). Therefore, choosing a carrier that can pass through the BBB is very important for glioma treatment.…”

Section: Introductionmentioning

confidence: 99%

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

et al. 2021

View full text Add to dashboard Cite

Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in treating and managing this disease, consequently, new therapeutic strategies must be developed. Crossing the blood-brain barrier (BBB) is another challenge for most drug vectors and therapy medications. Filamentous bacteriophage can enter the brain across the BBB. Compared to traditional drug vectors, phage-based drugs offer thermodynamic stability, biocompatibility, homogeneity, high carrying capacity, self-assembly, scalability, and low toxicity. Tumor-targeting peptides from phage library and phages displaying targeting peptides are ideal drug delivery agents. This review summarized recent studies on phage-based glioma therapy and shed light on the developing therapeutics phage in the personalized treatment of glioma.

show abstract

Photodynamic Priming Modulates Endothelial Cell–Cell Junction Phenotype for Light-activated Remote Control of Drug Delivery

Cited by 11 publications

References 91 publications

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

Contact Info

Product

Resources

About